[go: up one dir, main page]

HK1032542A1 - Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator - Google Patents

Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator

Info

Publication number
HK1032542A1
HK1032542A1 HK01103236A HK01103236A HK1032542A1 HK 1032542 A1 HK1032542 A1 HK 1032542A1 HK 01103236 A HK01103236 A HK 01103236A HK 01103236 A HK01103236 A HK 01103236A HK 1032542 A1 HK1032542 A1 HK 1032542A1
Authority
HK
Hong Kong
Prior art keywords
nmda receptor
receptor complex
opioid antagonist
treatment
combination
Prior art date
Application number
HK01103236A
Other languages
English (en)
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Phillipe Durbin
Original Assignee
Merck Sante Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante Sas filed Critical Merck Sante Sas
Publication of HK1032542A1 publication Critical patent/HK1032542A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK01103236A 1998-03-26 2001-05-08 Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator HK1032542A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (en) 1998-03-26 1998-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
PCT/EP1999/002337 WO1999048500A1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (1)

Publication Number Publication Date
HK1032542A1 true HK1032542A1 (en) 2001-07-27

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01103236A HK1032542A1 (en) 1998-03-26 2001-05-08 Combination for the treatment of alcohol dependence containing an opioid antagonist and nmda receptor complex modulator

Country Status (18)

Country Link
US (1) US6512009B1 (cs)
EP (2) EP0945133A1 (cs)
KR (1) KR20010034678A (cs)
AT (1) ATE230993T1 (cs)
AU (1) AU758569B2 (cs)
BR (1) BR9909138A (cs)
CA (1) CA2325739C (cs)
CZ (1) CZ296367B6 (cs)
DE (1) DE69904922T2 (cs)
DK (1) DK1063995T3 (cs)
ES (1) ES2190205T3 (cs)
HK (1) HK1032542A1 (cs)
HU (1) HU226555B1 (cs)
NO (1) NO319313B1 (cs)
PL (1) PL193241B1 (cs)
RU (1) RU2226107C2 (cs)
SK (1) SK284623B6 (cs)
WO (1) WO1999048500A1 (cs)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1243543C (zh) * 1998-07-20 2006-03-01 派普泰克有限公司 生物植入物配方
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
CA2779723C (en) 2002-12-13 2014-03-25 Durect Corporation Oral drug delivery system
WO2004056337A2 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
CA2526101A1 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
AU2008335809A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
JP2011515076A (ja) 2008-02-28 2011-05-19 ユニバーシティ オブ バージニア パテント ファウンデーション セロトニン輸送体遺伝子およびアルコール中毒症の処置
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
SI2801625T1 (en) 2010-07-02 2018-04-30 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug addiction
WO2013036721A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
US20240350433A1 (en) * 2021-08-17 2024-10-24 Yale University Treatment compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
WO1997033581A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds

Also Published As

Publication number Publication date
SK284623B6 (sk) 2005-08-04
EP1063995A1 (en) 2001-01-03
DE69904922T2 (de) 2004-01-08
RU2226107C2 (ru) 2004-03-27
SK14282000A3 (sk) 2001-05-10
HU226555B1 (en) 2009-03-30
WO1999048500A1 (en) 1999-09-30
BR9909138A (pt) 2000-12-05
NO20004788L (no) 2000-11-24
US6512009B1 (en) 2003-01-28
HUP0101546A3 (en) 2002-10-28
CA2325739A1 (en) 1999-09-30
ATE230993T1 (de) 2003-02-15
PL193241B1 (pl) 2007-01-31
CZ20003525A3 (cs) 2001-04-11
NO20004788D0 (no) 2000-09-25
AU3522699A (en) 1999-10-18
AU758569B2 (en) 2003-03-27
HUP0101546A2 (hu) 2001-09-28
DK1063995T3 (da) 2003-03-10
CZ296367B6 (cs) 2006-02-15
PL343069A1 (en) 2001-07-30
DE69904922D1 (de) 2003-02-20
KR20010034678A (ko) 2001-04-25
ES2190205T3 (es) 2003-07-16
EP0945133A1 (en) 1999-09-29
CA2325739C (en) 2007-05-15
EP1063995B1 (en) 2003-01-15
NO319313B1 (no) 2005-07-11

Similar Documents

Publication Publication Date Title
PL343069A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
HUP9900183A3 (en) Oral fast-dissolving pharmaceutical compositions for dopamine agonists
ZA962536B (en) Pharmaceutical composition for transdermal administration.
ES2181055T3 (es) Formulaciones galenicas que contienen antagonistas de opiaceos.
IL116673A (en) Stable oral pharmaceutical composition containing an acid labile benzimidazole
HUP9701694A3 (en) Indolinone derivatives for the treatment of disease, use thereof, pharmaceutical compositions containing these compounds
EP0749751A3 (en) Pharmaceutical composition for use in the treatment of diabetes
MX9706449A (es) Composicion farmaceutica para compuestos de piperidinalcanol.
UA66750C2 (en) Substituted 1-phenylpirazole 3-carboxamides, a method for the preparation thereof and intermediary compounds, pharmaceutical composition having affinity to neurotensin receptors
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
GB9917822D0 (en) Nmda antagonist
HUP0203597A3 (en) Pharmaceutical compositions containing zolmitriptan, process for their preparation and their use
CA2270177A1 (en) Transdermal administration of ment
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
UA41978C2 (uk) N-метил-n-[(1s)-1-феніл-2-((3s)-3-гідроксипіролідин-1-іл)етил]-2,2- дифенілацетамід гідрохлорид, спосіб його отримання та фармацевтична композиція
GB9907571D0 (en) Compounds
IL114673A (en) Pharmaceutical compositions containing protein for oral administration
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
HUP9801879A3 (en) Pyridazinone-derivatives as endothelin-receptor antagonists, use thereof, pharmaceutical compositions containing these compounds and process for the preparation of the compounds and the compositions
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
AU2882699A (en) Stabilizing composition for pharmaceutical dosage forms

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140326